8-K: Revelation Biosciences Implements 1-for-30 Reverse Stock Split

Revelation Biosciences has enacted a 1-for-30 reverse stock split, effective January 25, 2024, to consolidate its outstanding shares.

Summary

• Revelation Biosciences, Inc. has completed a reverse stock split at a ratio of 1-for-30.
• The reverse stock split was approved by stockholders at a special meeting on January 17, 2024.
• The reverse stock split became effective on January 25, 2024, at 12:01 a.m. Eastern Standard Time.
• Every 30 shares of existing common stock were converted into one new share.
• Approximately 209,911 shares of common stock will be outstanding after the reverse split.
• Fractional shares will be rounded up to the next whole share.
• Outstanding equity awards and warrants will be adjusted proportionally to reflect the reverse split.
• The number of shares available under the company's equity incentive plans will also be adjusted proportionally.
• The new CUSIP number for the common stock is 76135L507.

Sentiment

Score: 6

Explanation: The document describes a reverse stock split, which is a neutral event. While it can be a sign of financial challenges, it is also a common corporate action to maintain listing compliance. The sentiment is therefore neutral to slightly positive as it is a necessary step for the company.

Positives

• The reverse stock split was approved by shareholders, indicating support for the company's strategy.
• The rounding up of fractional shares ensures that no shareholder is disadvantaged by the split.

Risks

• Reverse stock splits can sometimes be perceived negatively by the market, potentially impacting investor confidence.
• The reduction in the number of outstanding shares may increase volatility.

Future Outlook

The company's common stock will begin trading on a post-split basis on January 25, 2024, under the existing trading symbol REVB.

Management Comments

• The board of directors determined the specific ratio for the reverse stock split.
• The Chief Financial Officer, Chester S. Zygmont, III, signed the report on behalf of the company.

Industry Context

Reverse stock splits are often used by companies to increase their stock price and maintain listing requirements on exchanges like Nasdaq. This action is not uncommon in the biotechnology sector, where companies may need to raise capital or improve their stock's appeal to investors.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing low share prices, particularly in the biotech industry.
• Many companies in similar situations have implemented reverse stock splits in the range of 1-for-5 to 1-for-50, making Revelation Biosciences' 1-for-30 split within the typical range.
• For example, companies like Agenus Inc. and Ocugen Inc. have also recently undertaken reverse stock splits to maintain their Nasdaq listing.

Corporate Governance

Stakeholder Impact

• Shareholders will have their number of shares reduced by a factor of 30, but the value of their holdings should remain relatively constant.
• Holders of equity awards and warrants will have their awards adjusted proportionally.
• The reverse stock split may impact the perceived value of the company by investors.

Next Steps

• The company's common stock will begin trading on a post-split basis on January 25, 2024.
• Shareholders will see their holdings adjusted to reflect the 1-for-30 reverse stock split.

Key Dates

Keywords

reverse stock split, common stock, share consolidation, equity awards, warrants, CUSIP, REVB